Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. proteinplus

ProteinPlus SIGNED

Let's give the world appetite for health

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ProteinPlus project word cloud

Explore the words cloud of the ProteinPlus project. It provides you a very rough idea of what is the project "ProteinPlus" about.

disruptive    launch    europeans    generating    founded    sustainability    ingredient    oral    compatibility    medical    lab    patented    meet    specially    million    half    2020    nice    technological    mass    manufacturers    capital    proving    sent    volumes    170bn    leader    revenues    ingredients    reducing    unilever    tastier    healthier    patients    prevents    copy    prepare    supplements    standards    fresenius    10bn    nutricia    health    burden    dominated    employees    dramatically    emulsar    taste    nutritional    abbott    deficiencies    2012    invented    bad    designed    plus    proved    nutrition    reaching    limiting    manufacture    levels    proof    nanotechnology    tons    compliance    effectiveness    formulated    savings    treatment    75m    ons    illness    casino    optimize    density    competitiveness    validate    eacute    clinical    food    foods    dense    create    proteins    120    induce    commercial    volume    smart    hundreds    malnutrition    33    public    healthcare    barrier    50    market    protein    hyperproteinic    emulsion    overcomes    disease    industrial    transition    sizes    gap    2004    reduce    nestl    full    portion   

Project "ProteinPlus" data sheet

The following table provides information about the project.

Coordinator		 EMULSAR 

Organization address
address: 26-28 rue Marius Aufan
city: Levallois-Perret
postcode: 92300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.emulsar.com/
 Total cost 2˙449˙800 €
 EC max contribution 1˙714˙860 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMULSAR FR (Levallois-Perret) coordinator 1˙714˙860.00

Map

 Project objective

Disease-related malnutrition affects 33 million Europeans, a burden of 170bn€ for the EU. Oral Nutritional Supplements (ONS) are specially formulated foods designed to meet patients’ nutritional deficiencies during illness. This $10Bn ONS market is dominated by Nutricia, Nestlé, Fresenius & Abbott.

However, large portion sizes and bad taste in ONS induce very low levels of treatment compliance (50%), dramatically limiting effectiveness. Manufacturers face a technological barrier that prevents them from increasing protein density and thus reducing volume.

The aim of the project is to bring to the market a disruptive hyperproteinic ingredient – Protein Plus© - for ONS manufacturers, that overcomes this technology gap.

Founded in 2004, EMULSAR invented and patented its Smart Emulsion Nanotechnology© (SENT©), used to manufacture disruptive ingredients for health and nutrition. Since 2012, SENT© has produced hundreds of tons of food ingredients (used by Casino, Unilever…to create healthier & tastier products), proving its industrial sustainability and compatibility with commercial food standards.

In Phase 1, we proved (at lab-scale) that by applying SENT© to proteins, we can produce a protein-dense ingredient that makes it possible to reduce current ONS volumes by half.

Our Phase 2 objectives are to optimize our Protein Plus© ingredient, validate the industrial process, establish clinical proof of improved ONS compliance & prepare our market launch.

Our project will improve the competitiveness of ONS products, create public healthcare savings and enhance Europe’s health capital. For EMULSAR, the ONS market is the best path for becoming a European technology leader in health food, allowing EMULSAR to transition from nice-to-have applications (mass-market food) to must-have applications (medical nutrition). The current project is the key to reaching the full commercial potential of our nanotechnology, generating 75M€ in revenues & managing 120 employees by 2020.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROTEINPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROTEINPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

PLUGandFLOW (2017)

VessConnect “Plug Flow” innovative technology providing patients a safer, more effective and less costly procedure for vascular anastomosis

Read More  

NAS (2018)

Nexilis augmentation system

Read More